Baseline risk of hematologic malignancy at initiation of frontline PARP inhibitor maintenance for BRCA1/2-associated ovarian cancer

Poly(ADP-ribose) polymerase inhibitors (PARPi) are FDA approved as frontline maintenance for BRCA-associated advanced stage high-grade ovarian cancer (HGOC), having demonstrated an unprecedented improvement in relapse-free survival. Myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) are...

Descripción completa

Detalles Bibliográficos
Autores principales: Navitski, Anastasia, Al-Rawi, Duaa H., Liu, Ying, Rubinstein, Maria M., Friedman, Claire F., Rampal, Raajit K., Mandelker, Diana L., Cadoo, Karen, O'Cearbhaill, Roisin E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Case Reports and Case Series
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8651772/
https://www.ncbi.nlm.nih.gov/pubmed/34926756
http://dx.doi.org/10.1016/j.gore.2021.100873

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8651772/
https://www.ncbi.nlm.nih.gov/pubmed/34926756
http://dx.doi.org/10.1016/j.gore.2021.100873

Ejemplares similares